MNOV
MediciNova, Inc.
Biotechnology
Market Cap$71M
5Y Perf.-72.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MNOV vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$84M
5Y Perf.-97.2%
MNOV vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNOV | NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $71M | $84M |
| Revenue (TTM) | $410K | $242K |
| Net Income (TTM) | $-12M | $-38M |
| Gross Margin | 7.6% | 59.5% |
| Operating Margin | -32.4% | -63.0% |
| Total Debt | $194K | $631K |
| Cash & Equiv. | $31M | $8M |
MNOV vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNOV
NRXP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MediciNova, Inc. (MNOV) | 100 | 27.2 | -72.8% |
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNOV vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNOV leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NRx Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MNOV
MediciNova, Inc.
The Income Pick
MNOV carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.31
- -79.0% 10Y total return vs NRXP's -96.8%
- Lower volatility, beta 0.31, Low D/E 0.5%, current ratio 8.16x
Best for: income & stability and long-term compounding
NRXP
NRx Pharmaceuticals, Inc.
The Growth Play
NRXP is the clearest fit if your priority is growth exposure.
- EPS growth 43.9%
- 101.1% revenue growth vs MNOV's -8.8%
- +58.9% vs MNOV's -2.0%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs MNOV's -8.8% |
| Quality / Margins | MNOV | -29.3% margin vs NRXP's -157.3% |
| Stability / Safety | MNOV | Beta 0.31 vs NRXP's 1.91 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NRXP | +58.9% vs MNOV's -2.0% |
| Efficiency (ROA) | MNOV | -26.3% ROA vs NRXP's -489.9% |
MNOV vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
MNOV vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNOVLAGGINGNRXP
NRXPNRx Pharmaceuticals, …
0leads
MNOVMediciNova, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs NRXPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MNOV4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNOV3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
MNOV4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MNOV leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
MNOV is the larger business by revenue, generating $409,657 annually — 1.7x NRXP's $242,000. MNOV is the more profitable business, keeping -29.3% of every revenue dollar as net income compared to NRXP's -157.3%.
| Metric | MNOVMediciNova, Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $409,657 | $242,000 |
| EBITDAEarnings before interest/tax | -$13M | -$31M |
| Net IncomeAfter-tax profit | -$12M | -$38M |
| Free Cash FlowCash after capex | -$10M | -$12M |
| Gross MarginGross profit ÷ Revenue | +7.6% | +59.5% |
| Operating MarginEBIT ÷ Revenue | -32.4% | -63.0% |
| Net MarginNet income ÷ Revenue | -29.3% | -157.3% |
| FCF MarginFCF ÷ Revenue | -23.9% | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +4.7% | -80.0% |
MNOV leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — MNOV and NRXP each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MNOVMediciNova, Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $71M | $84M |
| Enterprise ValueMkt cap + debt − cash | $41M | $77M |
| Trailing P/EPrice ÷ TTM EPS | -6.04x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 173.60x | 68.92x |
| Price / BookPrice ÷ Book value/share | 1.71x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MNOV and NRXP each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNOV leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs MNOV's 3/9, reflecting solid financial health.
| Metric | MNOVMediciNova, Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | -28.9% | — |
| ROA (TTM)Return on assets | -26.3% | -4.9% |
| ROICReturn on invested capital | -85.5% | — |
| ROCEReturn on capital employed | -28.0% | — |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$31M | -$7M |
| Cash & Equiv.Liquid assets | $31M | $8M |
| Total DebtShort + long-term debt | $194,331 | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -24.18x |
MNOV leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
MNOV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNOV five years ago would be worth $3,625 today (with dividends reinvested), compared to $99 for NRXP. Over the past 12 months, NRXP leads with a +58.9% total return vs MNOV's -2.0%. The 3-year compound annual growth rate (CAGR) favors MNOV at -12.8% vs NRXP's -21.1% — a key indicator of consistent wealth creation.
| Metric | MNOVMediciNova, Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | +9.0% | +16.4% |
| 1-Year ReturnPast 12 months | -2.0% | +58.9% |
| 3-Year ReturnCumulative with dividends | -33.8% | -50.8% |
| 5-Year ReturnCumulative with dividends | -63.7% | -99.0% |
| 10-Year ReturnCumulative with dividends | -79.0% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -12.8% | -21.1% |
MNOV leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNOV and NRXP each lead in 1 of 2 comparable metrics.
Risk & Volatility
MNOV is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than NRXP's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.4% from its 52-week high vs MNOV's 74.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MNOVMediciNova, Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.31x | 1.91x |
| 52-Week HighHighest price in past year | $1.96 | $3.84 |
| 52-Week LowLowest price in past year | $1.17 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +74.0% | +79.4% |
| RSI (14)Momentum oscillator 0–100 | 49.6 | 64.4 |
| Avg Volume (50D)Average daily shares traded | 49K | 914K |
Evenly matched — MNOV and NRXP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MNOVMediciNova, Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNOV leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallMediciNova, Inc. (MNOV)Leads 3 of 6 categories
Loading custom metrics...
MNOV vs NRXP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — MNOV or NRXP?
Over the past 5 years, MediciNova, Inc.
(MNOV) delivered a total return of -63. 7%, compared to -99. 0% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: MNOV returned -79. 0% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — MNOV or NRXP?
By beta (market sensitivity over 5 years), MediciNova, Inc.
(MNOV) is the lower-risk stock at 0. 31β versus NRx Pharmaceuticals, Inc. 's 1. 91β — meaning NRXP is approximately 517% more volatile than MNOV relative to the S&P 500.
03Which is growing faster — MNOV or NRXP?
On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc.
grew EPS 43. 9% year-over-year, compared to -4. 3% for MediciNova, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — MNOV or NRXP?
NRx Pharmaceuticals, Inc.
(NRXP) is the more profitable company, earning -23. 4% net margin versus -29. 3% for MediciNova, Inc. — meaning it keeps -23. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRXP leads at -1324. 4% versus -32. 4% for MNOV. At the gross margin level — before operating expenses — NRXP leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — MNOV or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is MNOV or NRXP better for a retirement portfolio?
For long-horizon retirement investors, MediciNova, Inc.
(MNOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31)). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNOV: -79. 0%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between MNOV and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.